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Abstract: Protein kinase CK2 has received a surge of attention in recent years due to the evidence of
its overexpression in a variety of solid tumors and multiple myelomas as well as its participation in
cell survival pathways. CK2 is also upregulated in the most prevalent and aggressive cancer of brain
tissue, glioblastoma multiforme, and in preclinical models, pharmacological inhibition of the kinase
has proven successful in reducing tumor size and animal mortality. CK2 is highly expressed in the
mammalian brain and has many bona fide substrates that are crucial in neuronal or glial homeostasis
and signaling processes across synapses. Full and conditional CK2 knockout mice have further
elucidated the importance of CK2 in brain development, neuronal activity, and behavior. This review
will discuss recent advances in the field that point to CK2 as a regulator of neuronal functions and as
a potential novel target to treat neurological and psychiatric disorders.
Keywords: CK2; neurodegeneration; synapse; signaling; CK2 inhibitors; GPCRs; CK2 substrates;
CK2 knockout
1. Introduction
CK2 (formerly Casein Kinase 2) is a heterotetrameric kinase consisting of two catalytic (α or α′)
and two regulatory β subunits. It is constitutively active and ubiquitously expressed.
While in some instances several growth factors and neurotrophins have been shown to boost CK2
activity [1–3], the general consensus to date is that CK2 activity is dependent on its microenvironment
within multimolecular complexes which can confer substrate specificity [4] or binding and recruitment
to activity-regulated proteins such as, for example, Calmodulin [5,6].
CK2 partakes in signal transduction pathways that are crucial for cell survival such as the AKT
pathway. It was shown to directly phosphorylate AKT1 (Ser129) to render AKT more active [7].
CK2 also phosphorylates and inactivates the lipid phosphatase PTEN which, by dephosphorylating
phosphatidylinositol-3,4,5-trisphosphate (PIP3), reverses the activation of the AKT pathway [8].
Several other modulators of the AKT pathway are also substrates of CK2, making this kinase, clearly,
an influential activator of the survival pathway. Studies have demonstrated that overexpression of CK2
potentiates tumor growth through suppression of apoptosis, promotion of angiogenesis, and signaling
through PI3K-AKT, Wnt, and NF-kB [9]. Cancer cells and tissue were also shown to undergo necrosis
in the presence of CK2 inhibitor [10].
Based on the minimal substrate consensus sequence that requires an acidic residue at position
n + 3 [11,12], it is not too surprising that, to date, 356 proteins have been identified that are
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phosphorylated in vitro and in vivo by CK2 [13] and, thus, represent a large pool of bona fide substrates,
attesting to the important role of CK2 as a multifunctional kinase.
In this review, we focus on recent advances in the characterization of brain-derived CK2 substrates
that have been studied in an in vivo context and may have an impact in neurodegenerative disorders.
We will discuss these substrates first in their roles in the healthy brain, followed by a section on CK2 in
the context of brain disorders, and we point out several instances in which CK2 might prove a valid
novel target for the treatment of neurological and neuropsychiatric disorders.
2. CK2 Expression in the Adult Mouse Brain
CK2 is ubiquitously expressed in the periphery, and this is true for the brain as well. However,
differences in expression in subregions of the brain, both on the transcript level, as can be derived from
the Allen Brain Atlas, as well as on the level of protein have been observed [14,15]. Discerning
the expression pattern of the individual subunits, CK2β mRNA levels do not appear balanced
to the amounts of the combined CK2α and CK2α′ expression, but reflects CKα′ expression more
closely. On the protein level, throughout the brain, there is a predominance of α over α′ subunits [14].
For example, in mouse striatum, a region of particular interest due to its role in movement control
and reward processing, the molar ratio of CK2α:CK2α′ is 8:1. Even in the region with the highest
CK2α′ protein level (hippocampus), the ratio of CK2α:CK2α′ (4:1) favors CK2α. Now, we are adding
to the in situ hybridization and western blotting data immunohistochemical analyses of CK2α, α′
and β in adult mouse sagittal slices. These images depict protein expression at a much more detailed
level than western blotting analysis, which is limited by the manual dissection technique. Overall,
mRNA levels correspond to protein levels of the different subunits across brain regions (Figure 1A),
however, some interesting patterns could be detected.
In the hippocampus, CK2α and CK2α′ proteins are present, and protein expression corresponds
to mRNA levels. For CK2β, mRNA levels are the highest in the hippocampus when compared to other
brain regions, but at the protein level, CK2β appears absent in dentate gyrus or the CA1, CA2, CA3
regions (Figure 1A, CA2 in higher resolution in Figure 1B). In most other regions, CK2β overlaps fully
with CK2α, and we show here the prefrontal cortex as a representative example (Figure 1B’).
We found high expression of the three CK2 subunits in the pontine gray nucleus (PG), a part of
the brain stem regulating motor function (Figure 1A). This area, however, is also characterized by
high cell density (as visualized with a neuron-specific marker NeuN which is present in all neurons
with the exception of cerebellar Purkinje cells, olfactory mitral cells, Cajal-Retzius cells, neurons of the
inferior olive, and a few others) that causes the elevated immunosignal [16].
In the olfactory bulb, CK2α is very highly expressed, and, thus, the ratio of CK2α:CK2α′ is
elevated to 24:1 [14]. Immunohistochemistry confirms this result. On cellular resolution, CK2β
and CK2α co-localize, while CK2α′ is not detected despite significant mRNA levels in that region
(Figure 1C). CK2β was counterstained with NeuN; the neuronal marker is absent from the CK2β
expressing cells, and by deduction also from CK2α expressing cells. These cells supposedly are
olfactory mitral cells which cannot be stained with NeuN [16] (Figure 1C).
When examining the cerebellum, we found CK2α and CK2β to be homogenously present in the
large GABAergic Purkinje cells, while CK2α′ is expressed in a scattered manner. All isoforms are
sporadically present in the molecular and granular layers of the cerebellar folium (Figure 1D).
The fact that no brain region was found where the CK2α′ level dominates does not imply that
CK2α′ does not have a specialized vital function in the brain such as the binding to specific partners
or localization to specific microdomains or subcellular structures. In fact, for example, the clustered
pattern seen in the Purkinje cells of the cerebellum may be of physiological importance.
It will be interesting to take a closer look at the expression profile on a cellular level, including the
use of glial markers and assess the differences in subunit expression in different cell types.
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Figure 1. A–D: Immunohistochemical analysis of sagittal brain slices of adult C57BL/6 mice. PFA 
perfused brains were sliced (40 µm) and incubated with α-CK2α, α-CK2α’ (both Abcam), α-CK2β 
(gift from Dr. O. Filhol Grenoble) and α-NeuN (Cell Signaling) followed by incubation with 
secondary antibodies, Alexa 546/488 α-rabbit/α-mouse (Fisher Scientific). Imaging was performed 
using a Zeiss LSM710 laser-scanning confocal microscope. Slices were stained for CK2α, CK2α’ and 
CK2β (A), the hippocampal CA1region and PFC were stained for CK2α and CK2β (B). Olfactory bulb 
was stained for CK2β and NeuN, CK2α and CK2α’. (C) Cerebellum was stained for CK2α, CK2 β 
and NeuN (D) and for CK2α’. PG: Pontine gray nucleus; white bars = 100 µM. 
3. Inhibitors 
A multitude of CK2 inhibitors are available, with varying specificities and efficacies [17,18]. 
Determining the various roles of CK2 in the brain has been difficult in part because of the poor 
permeability of chemical CK2 inhibitors into the brain due to the blood brain barrier (BBB). This 
interface separates the brain from the circulatory system, protects it from the influx of potentially 
harmful chemicals or organisms, and at the same time enables the transport of essential molecules 
bi-directionally. It is comprised of endothelial cells as well as astrocytes and pericytes adjacent to 
small capillaries. The high level of expression of efflux transporters (such as P-glycoprotein) in the 
BBB further prevents many molecules from reaching the brain. Drugs that can diffuse through the 
BBB must be of small molecular size (less than 500 Da), highly lipophilic, and not ionized at 
physiological pH [19]. This is not the case for the more specific CK2 inhibitors such as DMAT, TBB, 
and CX4945 which are relatively hydrophilic. 
Thus far, however, one CK2 inhibitor has proven successful in reducing the growth of 
glioblastoma implanted intracranially in mice [20]. Mice were administered orally with CX4945, the 
sole CK2 inhibitor to date that has been proven to be safe and efficient in a clinical phase I/II trial in 
humans (ClinicalTrials.gov Identifier: NCT02128282). It has been shown that glioblastoma hamper 
the integrity of the BBB and this may have enabled the systemically administrated CX4945 to reach 
the brain tumor in sufficient quantities [21]. 
Figure 1. A–D: Immunohistochemical analysis of sagittal brain slices of adult C57BL/6 mice.
PFA perfused brains were sliced (40 µm) and incubated with α-CK2α, α-CK2α′ (both Abcam),
α-CK2β (gift from Dr. O. Filhol Grenoble) and α-NeuN (Cell Signaling) followed by incubation with
secondary antibodies, Alexa 546/488 α-rabbit/α-mouse (Fisher Scientific). Imaging was performed
using a Zeiss LSM710 laser-scanning confocal microscope. Slices were stained for CK2α, CK2α′ and
CK2β (A), the hippocampal CA1region and PFC were stained for CK2α and CK2β (B). Olfactory bulb
was stained for CK2β and NeuN, CK2α and CK2α′. (C) Cerebellum was stained for CK2α, CK2 β and
NeuN (D) and for CK2α′. PG: Pontine gray nucleus; white bars = 100 µM.
3. Inhibitors
A multitude of CK2 inhibitors are available, with varying specificities and efficacies [17,18].
Determining the various roles of CK2 in the brain has been difficult in part because of the poor
permeability of chemical CK2 inhibitors into the brain due to the blood brain barrier (BBB).
This interface separates the brain from the circulatory system, protects it from the influx of potentially
harmful chemicals or organisms, and at the same time enables the transport of essential molecules
bi-directionally. It is comprised of endothelial cells as well as astrocytes and pericytes adjacent to small
capillaries. The high level of expression of efflux transporters (such as P-glycoprotein) in the BBB
further prevents many molecules from reaching the brain. Drugs that can diffuse through the BBB
must be of small molecular size (less than 500 Da), highly lipophilic, and not ionized at physiological
pH [19]. This is not the case for the more specific CK2 inhibitors such as DMAT, TBB, and CX4945
which are relatively hydrophilic.
Thus far, however, one CK2 inhibitor has proven successful in reducing the growth of glioblastoma
implanted intracranially in mice [20]. Mice were administered orally with CX4945, the sole CK2
inhibitor to date that has been proven to be safe and efficient in a clinical phase I/II trial in humans
(ClinicalTrials.gov Identifier: NCT02128282). It has been shown that glioblastoma hamper the integrity
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of the BBB and this may have enabled the systemically administrated CX4945 to reach the brain tumor
in sufficient quantities [21].
In our laboratory, we have performed dose and time course experiments using intraperitoneal
(i.p.) injections of CX4945 in adult mice, followed by Western blotting assessment of several CK2
phosphorylation sites or of sites within the AKT pathway. At doses lower or equal 60 mg/kg,
no significant reduction of these sites in striatal and prefrontocortical tissue could be detected, however,
at a relatively high dose of 75 mg/kg, 2 h post-injection, the direct pS129 Akt site as well as the pS473
AKT and pS235/236 S6 ribosomal protein sites were reliably reduced, indicating that at this dose in
healthy adult mice, with an intact BBB, the compound reached the brain (unpublished data). However,
i.p. injection of this dose is not advisable when one aims to study CK2-dependency of certain behaviors
since the mice become somewhat rigid, which indicates peripheral or central side effects that need to
be further studied. The more preferable means of administration is to infuse the drug via implanted
cannulae, allowing for intracranial infusion without the need of concurrent anesthesia.
Bi-substrate CK2 inhibitors, interacting with both the adenosine triphosphate (ATP) and the
phospho-acceptor substrate-binding sites have been the latest addition to the collection of CK2
inhibitors. While highly effective [22], thus far, these types of compounds are unable to penetrate cells
or the BBB.
New strategies are being developed to overcome the restraints of the BBB, such as the use of
liposomal, magnetic, or polymeric nanoparticles that are either coated or conjugated with targeting
moieties that enable carrier-, receptor-, and absorption-mediated passage through the BBB (for a review
see [19]).
One such example for CK2 is the successful delivery of tenfibgen nanocapsules with a siRNA
CK2 cargo via intravenous administration, which resulted in significant xenograft tumor reduction
in a mouse model of prostate cancer [23]. Recently, a dual approach was tested: CK2 and epidermal
growth factor receptor (EGFR), both of which are overexpressed in glioblastoma [24], were targeted
by morpholino oligomeres attached to nanobioconjugates [25], in a mouse model of intracranial
human glioblastoma. This lead to increased animal survival and concomitantly reduced pro-survival
(AKT, STAT, Wnt) signaling. The nanoconjugates were linked to anti-tranferrin antibody that enabled
BBB passage and an anti-EGFR antibody to attach to cancer cells [25]. One could envisage the packaging
of CK2 inhibitors into nanocapsules as well.
4. CK2 Knockout Mice
Knockout (KO) mice are in many ways superior to inhibitors when one wants to detect
physiological functions of a specific gene product since they allow for deletion or insertion of a
specific gene through homologous recombination, thus, not affecting other genes. However, one has to
be aware that developmental adaptations may occur, especially in full knockout or conditional models
with early embryonic Cre recombinase expression. KO mice have clearly shaped our understanding of
the crucial role of CK2 in development: full CK2β knockout mice are embryonic lethal. The embryos
are absorbed on embryonic day E7.5 [26]. Conditional CK2β KO mice were generated and crossed
with a Nestin-Cre driver to generate mice deficient in CK2β in the central nervous system, but mutant
pups died shortly after birth [27]. Interestingly, the CK2β protein was detected in KO mice six days
after onset of Cre expression, which could be rationalized by the long stability of the CK2β protein
once integrated in the CK2 holoenzyme. It is interesting to note that CK2α expression was not altered
in the KO mice [27].
A full CK2α KO mouse line was also generated: while the heterozygous offspring are born at
the Mendelian ratio, the homozygous embryos die mid-gestation (E11.5) [28]. The strongest defects
were seen in the heart and neural tube, pointing towards an important role of CK2 in brain and heart
development. Interestingly, expression of CK2β is reduced while CK2α′ expression is unaffected in
the CK2α KO [28,29].
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CK2α′ KO mice are viable and do not exhibit an obvious phenotype. Only homozygous males are
infertile because spermatocytes frequently undergo apoptosis or have abnormal heads (as in the human
condition globozoospermia) [30]. It is of interest to note that due to the lack of apoptosis-positive
cells (TUNEL assay) in the CK2α and CK2β KO embryos, it was suggested that, during embryonic
development, CK2α and CK2β are mainly controlling cell proliferation and not apoptotic events [29].
To study the role of CK2 in the brain, we generated CK2αfl/fl and CK2α′fl/fl lines. Mice lacking
CK2α′ in the forebrain (CK2α′fl/fl; CaMKII-Cre) were viable and did not display an obvious behavioral
or pathological phenotype. In contrast, neither the CK2αfl/fl; CaMKII-Cre or CK2αfl/fl; CK2α′fl/fl;
CaMKII-Cre were viable, the mice died perinatally [14]. CaMKII-Cre has been described as readily
detectable at postnatal day three [31], however, due to the perinatal death of our offspring, we suspect
that sub-threshold expression already occurs days earlier. The non-viability of the Cre-positive
offspring indicates that a short depletion of CK2 activity at the developmental stages around birth is
crucial for viability.
We also generated cell-specific neuronal KO mice by crossing the CK2α floxed animals with the
Drd1a-Cre or the Drd2-Cre driver lines which leads to ablation of CK2α in the dopamine D1 receptor
expressing cells of the striatum and cortex, and in the D2 receptor expressing cells of the striatum and
midbrain, respectively. Notably, the double KOs, homozygous for CK2α and α′ deletion, were not
viable with any of the Cre-driver lines tested. However, the single KOs homozygous for CK2α or α′
isoforms were viable with both the Drd1a-Cre and the Drd2-Cre driver mouse lines [32]. Cre expression
starts at E16 for the Drd1a-Cre and at E14 for Drd2-Cre [33,34]. Interestingly, expression of the β
subunit was not affected in the Drd1a-Cre-CK2α KO while it was significantly reduced in Drd2-Cre
CK2 KO.
The Drd1a-Cre CK2 KO mice exhibited distinct behavioral phenotypes including novelty-induced
hyperlocomotion and exploratory behavior, defective motor control, and motor learning. These traits
are indicative of dysregulated dopamine signaling and were rescued by dopamine D1 receptor
antagonist [32]. The underlying mechanisms involved in the phenotype are probably manifold:
in addition to altered D1 receptor homeostasis, altered synaptic activity may be involved, since, as will
be discussed in the next paragraph, CK2 was shown to regulate several glutamate receptors [5,6,35].
The importance of CK2 in the dopaminergic system is further highlighted by preliminary findings
indicating that in a mouse model of Parkinson’s disease, a response to the antiparkinsonian drug,
L-DOPA, namely uncontrollable dyskinesia, is affected in KO mice (unpublished data).
The floxed CK2α, CK2α′ and CK2β mouse lines are amenable to focal knockdown of CK2 since
Adeno-associated virus (AAV) or Lentivirus can be used to induce Cre recombinase in small to more
widespread areas around an injection site, depending on the viral serotype. This approach will certainly
be valuable to address whether a specific brain region mediates certain phenotypes.
5. Brain Specific Substrates
CK2 is a pleiotropic kinase with several hundred potential substrates [36]. Many substrates are
not only important in the periphery but have similar roles in the brain. An extensive review of such
substrates can be found in [37]. In this section, we aim to discuss in vivo substrates of CK2 that are
either specific to the brain or are crucial for healthy brain function. Many of these candidates are also
involved in brain disorders and suggest that CK2 could be a valid novel target for pharmacotherapy
for such disorders, as will be discussed in Section 6 of this review.
5.1. G Protein Coupled Receptors (GPCRs)
G protein coupled receptors (GPCRs) make up the largest protein family in the human genome and
consist of over 800 members [38]. These receptors mediate the biological actions of neurotransmitters,
hormones, pheromones, light, and calcium through the activation of one or more of the four G protein
families: Gαi/o, Gαq/11, Gαs, and Gα12/13. GPCR cell surface expression and coupling to G-proteins are
regulated by phosphorylation of their third intracellular loop and/or their C-terminal region by various
Pharmaceuticals 2017, 10, 7 6 of 17
Ser-Thr kinases, such as G protein-coupled receptor kinases (GRKs1–7) [39]. Binding of arrestins
to phosphorylated receptors results in uncoupling of the receptor, desensitization of the response,
and endocytosis of the receptor [39,40]. Second messenger-dependent protein kinases, such as protein
kinase A and protein kinase C, or CK1α, are also involved in GPCR desensitization [41]. More recently,
CK2 joined the pool of kinases that are capable of phosphorylating GPCRs. Torrecilla et al. showed
that the muscarinic M3 acetylcholine receptor is phosphorylated by CK2 in the third intracellular loop
upon agonist occupation [42]. However, in this case, no internalization except a signaling switch to a
Jun-kinase dependent pathway is induced. In pancreatic ß-cells, CK2 was shown to phosphorylate
the same receptor, M3 [43], with the effect of reduced insulin release. Both, CK2 inhibition and
knockdown of CK2α in β-cells resulted in M3 receptor-stimulated insulin release. Again, in this case,
phosphorylation did not affect receptor internalization or signaling. These two papers demonstrate
that CK2 is capable of affecting the same receptor, in different cell types, resulting in different outcomes.
The determination as to which outcome phosphorylation has most probably depends on the expression
of tissue-specific proteins and/or on the specific phosphorylation site.
A different involvement of CK2 in the regulation of GPCRs in the brain was identified following
a yeast-two-hybrid screen which yielded the G protein subunit Gαs as a CK2β interacting partner
in cultured cells and in brain tissue. The complex also contained CK2α, indicating that the CK2
holoenzyme is bound to Gαs [44]. The interaction was specific to Gαs since no other Gα subunit
precipitated with CK2β. Functionally, this interaction suggests negative regulation by CK2 of Gαs
signaling since CK2 inhibition or siRNA targeting CK2α reduced agonist-induced receptor endocytosis
in cultured cells and concomitantly enhanced receptor signaling. The regulatory effect of CK2 was also
observed for the Gαs-coupled adenosine A2a receptor [44]. The identity of the substrate for CK2 that
is involved in the regulation of Gαs-coupled receptor signaling is currently unknown.
The implication of the above studies is that CK2 has the potential to modulate a whole set of
GPCRs. It is estimated that roughly 15% of 170 well-studied non-olfactory GPCRs signal via Gαs [45].
Many of these GPCRs are expressed in the brain and are important pharmacological targets involved in
a variety of neurological disorders. For example, major depressive disorder, affecting up to 1 in 5 adults
in the USA [46] is related to dysfunction in brain serotonergic system. Three of the 14 serotonin receptor
subtypes are Gαs-linked and are, therefore, candidates for regulation by CK2. We have preliminary
evidence showing that one of these serotonin receptors, the 5-HT4 receptor, is regulated by CK2
(unpublished data).
Other neurological diseases in which Gαs coupled receptors play major roles are Parkinson’s
disease (PD) which is characterized by a hypersensitization of the Gαs-coupled dopamine D1 receptor.
In PD, adenosine A2a receptors control the activity of neurons that oppose the action of the D1 receptor.
A2a antagonists have been shown to exert potent anti-akinetic effects in animal models of PD and are
currently being evaluated in clinical trials [47]. One could, therefore, hypothesize that modulation of
CK2 could have beneficial effects via regulation of both D1 and A2a receptors in Parkinson‘s disease.
5.2. CK2 Substrates Involved in Synaptic Transmission
CK2 is present in the nucleus and cytoplasm of neurons, but it is also clearly localized at the plasma
membrane [44], and it is accumulated at the post-synaptic density in rat hippocampal and cortical
preparations [48]. In vitro, PSD-95 was shown to be a CK2 substrate [48]. CK2 was further shown
to co-localize with the N-methyl-D-aspartate receptors (NMDAR) subunit NR1 at the synapse [5].
Finally, CK2 activity was found to be enriched in synaptosomes [15].
Work of several groups has highlighted the importance of CK2 in the regulation of the ionotropic
glutamate receptors α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDAR.
With glutamate being the major excitatory neurotransmitter, it is logical that modulation of these
receptors impacts neuronal excitability and synaptic transmission. Both glutamate receptor types are
CK2 substrates, and their activity is modulated by CK2. For example, pharmacological inhibition
of CK2 reduced NMDAR activity [49]. The NR2B subunit of NMDAR is phosphorylated in vitro
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and in vivo by CK2, which leads to a disruption of receptor interaction with PSD-95 and a reduced
cell surface expression of the receptor [5]. This internalization process was a response to receptor
activation, suggesting that CK2 is involved in receptor desensitization. Since CK2 is known as a
constitutively active kinase, the question was how this subunit internalization may be regulated in
an activity-dependent manner. It was shown that the Ca2+/calmodulin-dependent protein kinase II
(CaMKII), activated through activity-induced calcium influx, recruits CK2 into a trimeric complex
together with NR2B. A NR2B mutant that cannot bind to CaMKII is less phosphorylated at the CK2
site (S1480) and has increased surface expression [6].
While the NR2A subunit of the NMDA receptor is not a CK2 substrate, is it still indirectly regulated
by CK2 since phosphorylation-dependent NR2B-endocytosis results in an increase in synaptic NR2A
expression. It was shown that this switch from NR2B to NR2A is crucial and corresponds to a surge in
CK2 expression during embryonic development and, as was later also shown in hippocampal neurons,
was dependent on NMDA receptor activity [35,50]. This switch from a NR2B to NR2A subunit in a
CK2 dependent manner, was also detected in adult brain hypothalamic neurons, resulting in increased
neuronal excitability [51]. The NMDA activity-dependent action of CK2 should be seen separately
from the action of CK2 on activating the receptor, which was proposed to be either mediated through a
different phosphorylation site or an indirect mechanism [49].
Recently, a role for CK2 in the regulation of cell surface expression of the AMPA receptor subunit
GluA1 was proposed in cultured hippocampal cells; in such a scenario, phosphorylation by CK2
leads cell surface accumulation of GluA1 as opposed to internalization of the NR2B subunit of the
NMDAR [52].
Glutamate receptors are not the only molecules involved in synaptic function that are CK2
substrates; others are, for example, synaptotagmin, a transmembrane protein involved in the synaptic
vesicle fusion with the presynaptic membrane [53], syntaxin, a synaptotagmin interacting protein [54],
and dynamin 1, a microtubule stimulated GTPase involved in endocytosis [53,55,56]. However,
these phosphorylation events have not, as yet, been detected in vivo.
Another family of membrane proteins that modulate synaptic activity are the voltage gated
sodium channels (NAvs). Recently, the CK2 inhibitor TBB was shown to reduce excitability of neurons
by abolishing CK2-mediated phosphorylation of the fibroblast growth factor receptor FGF14 and
reduced interaction of FGF14 with voltage gated sodium channels (NAv1.2 and 1.6) [57]. CK2 was
further found to directly phosphorylate the voltage gated sodium channel NAv1, thereby enhancing its
binding to ankyrin and accumulation at the axon initial element, an event which is necessary for fast
propagation of action potentials [58]. Small conductance Calcium-activated K+ (SK) channels are gated
by the Ca2+ sensor calmodulin. Phosphorylation of calmodulin by CK2 reduces its Ca2+ sensitivity
and leads to channel deactivation in xenopus oocytes [59].
Molecules involved in slow synaptic transmission are also phosphorylated in vitro by CK2.
These include the phosphatases PP2a and PP2c and the kinases PKA and PKC, to mention just a
few. For an extensive review on signaling proteins that are CK2 substrates, please refer to [3,36].
One example of an in vivo CK2 substrate that links cyclic AMP (cAMP) signaling to nuclear
responses, changes histone phosphorylation and transcription is the dopamine- and cAMP-regulated
neuronal phosphoprotein (DARPP-32), a regulator of the phosphatase PP1 that is highly expressed
in striatum [60]. CK2 phosphorylation of DARPP-32 enhances its potency to inhibit PP1 [61,62].
DARPP-32’s translocation to the nucleus, where it controls histone H3 phosphorylation and
transcriptional activation, depends on the phosphorylation state at the CK2 site. Mutation of the
CK2 phosphorylation site alters the behavioral effects of drugs of abuse and decreases motivation for
food [63].
5.3. Substrates Involved in Proteostasis
Many neurodegenerative disorders originate from protein misfolding processes. Examples are
Huntington’s disease, spinocerebellar ataxia, Parkinson’s and Alzheimer’s diseases. The presence
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of cellular defense mechanisms like molecular chaperones and proteasome degradation systems
prevent protein misfolding and aggregation, but these systems may not respond sufficiently under
conditions of permanently elevated levels of proteins with high aggregation propensities. Mis- or
unfolded proteins first aggregate to soluble oligomers, then to insoluble amyloid fibrils, which are
structurally defined by β strands. The capacity of protein quality control and degradation (proteostasis)
declines with aging, facilitating neurodegeneration as exemplified by the late onset of excessive
accumulation of amyloid-beta peptide (Aβ) and tau in Alzheimer’s disease, and α-synuclein in
Parkinson’s disease [64]. Chaperones have been shown to interfere at various steps of the aggregation
cascade including nucleation and fibril elongation and are members of diverse signaling pathways,
including the heat shock response activated after acute stress, the ubiquitin-proteasome system, and the
autophagosome-lysosome pathway [65,66]. While the aggregated protein itself, often inherited in
a mutated version, differs for each disease, the pathways controlling proteostasis are overarching
mechanisms of which CK2 has been shown to regulate several major players.
CK2 phosphorylates and modulates several chaperones such as Hsp90 as well as its co-chaperones
FKBP51, 52 and Cdc37. CK2-dependent phosphorylation of Cdc37 is essential for the chaperone
function of Hsp90-Cdc37 [67]. FKBP51 and 52 regulate, among others, steroid hormone receptor
activity: FKBP52 activates while FKBP51 inactivates these types of receptors. Phosphorylation by
CK2 completely abrogates FKBP52 regulation of receptor function, thus, leading to a reduction in
receptor activation. FKBP51 and FKBP52 are also discussed, together with Hsp90, for their impact
on tau phosphorylation and stability. Again, there seems to be an indication that both co-chaperones
act in opposing ways, with FKBP51 stabilizing tau and FKBP52 reducing tau stability [68]. To date,
these questions are not entirely resolved.
CK2 was shown to phosphorylate Hsf1, leading to nuclear accumulation of Hsf1 in vitro [69],
while mutation of phosphosites to alanine inhibited the transcriptional activity of Hsf1. This finding
could be of great interest since Hsf1 is the regulator of various chaperones, including Hsp70.
Enhancing the activity of the ubiquitin-proteasome pathway is a promising strategy to ameliorate
protein aggregation diseases. In this context, CK2 was found to modulate the expression of proteasome
genes via Nrf1 phosphorylation. Knockdown of CK2 enhances the Nrf1-dependent expression of
proteasome subunit genes and reduces the accumulation of ubiquitylated proteins in vitro in several
cell lines [70]. Like several other kinases, CK2 has been shown to target proteins for degradation
through ubiquitin-mediated proteolysis [71].
Taken together, like in other instances, CK2 has a bidirectional effect on the proteasome:
phosphorylation of certain substrates enhances their proteasomal degradation, while phosphorylation
of transcription factor Nrf1 reduces its activity to mediate expression of members of the proteasome
family. It is conceivable that the effect of Nrf1 on the synthesis of proteasome components and,
thus, on overall proteasome output, may outweigh the role of CK2 on targeting a handful of substrates
to the proteasome. However, one would need to integrate these data, as well as the effects on the
proteasome and on heat shock response, to estimate the net effect of CK2 on protein aggregation in
several systems, in cell culture, and, ideally, in preclinical models.
6. Diseases of the Human Brain
6.1. Glioblastoma
Glioblastoma multiforme (GBM) comprise 15% of all brain tumors and are the most aggressive
human glial tumors with a median survival of 14–15 months [72]. Unfortunately, tumors often become
drug-resistant and regrow despite chemotherapy. CK2α is overexpressed in human GBM; this is
caused by a gain in gene dosage of approximately 34% [20], while a 4-fold increase in CK2α protein is
measured [73].
Inhibition of CK2 activity through small molecule inhibitors or siRNA induced apoptosis, reduced
growth in GBM cells in mouse xenograft models of human GBMs [20] as well as in mice that had been
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injected intracranially with human GBM tumors. Concomitantly, CK2 inhibition lowered JAK/STAT
(Janus kinase/signal transducers and activators of transcription pathway) and NFkB activation as well
as the activation of survival markers of the AKT pathway and promoted survival of mice [20,25,74].
These data are very promising and clearly warrant clinical trials.
For the remainder of this section, we would like to focus on diseases where not proliferation
but rather cellular degeneration occurs, namely neurodegenerative diseases such as Parkinson’s and
Huntington’s diseases, Amyotrophic lateral sclerosis, and Alzheimer’s disease.
6.2. Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, affecting
as many as 2% of people 65 years or older [75]. It is characterized by symptoms such as tremor,
rigidity, bradykinesia, and gait disturbances. The major cytopathological markers of the disease are the
loss of dopaminergic neurons in the midbrain and the formation of Lewy bodies, mainly composed
of aggregated α-synuclein fibrils, in the remaining dopaminergic neurons [76]. Phosphorylation of
α-synuclein at Ser-129, close to its C-terminus is held as a hallmark of Parkinson’s disease mainly
because α-synuclein within Lewy bodies is extensively phosphorylated at this site. It was shown that
CK2 as well as polo-like kinase (PLK) phosphorylate soluble α-synuclein at S129, while PLKs are
most probably responsible for phosphorylation of aggregated α-synuclein [77]. Overexpression of
PLK but not CK2 in cultured cells increased phosphorylation of aggregated α-synuclein at S129 [78].
By employing a series of mutated substrates, in vitro experiments by Salvi et al. demonstrate that
the polo-like kinases PLK2 and PLK3 are more efficient at phosphorylating α-synuclein at this site
than CK2 [79]. Indeed, using striatal tissue from conditional CK2 KO mice (Drd1-Cre or Drd2-Cre)
we could not detect a reduction in pS129 α-synuclein (unpublished data) despite a 50% loss of CK2α
protein (and no compensatory upregulation of CK2α′). Thus, one can conclude that while CK2 is
an efficient in vitro kinase for this site, it is not the major kinase that performs this phosphorylation
in vivo. The physiological relevance of this phosphorylation is still heavily debated since experiments
in rats, mice, and drosophila as well as in tissue culture lead to opposing results and do not allow the
conclusion that pS129 a-synuclein is causal to the aggregation or to toxic effects [80].
Another protein that is localized to Lewy bodies and binds to α-synuclein is synphilin. It has
been reported that, in vitro, CK2 phosphorylates synphilin and thereby alters the interaction to
α-synuclein [81].
Based on our work with CK2 KO mice, we hypothesize that in addition to the potential CK2
substrates described above, CK2 may have a central role in modulating the brain’s responses to
dopamine depletion as well as to anti-parkinsonian treatment. We have shown that the activity of two
major dopamine responsive neuronal cell types in the striatum, namely the direct and indirect pathway
spiny projection neurons, is modulated by changes in expression and plasma membrane availability
of the dopamine D1 and the adenosine A2a receptors, respectively [32,44] Both these receptors are
primarily responsible for behavioral responses to dopamine and L-DOPA, therefore, we presume CK2
must have a role in Parkinson’s disease; this investigation is currently under way.
6.3. Huntington’s Disease
Huntington’s disease (HD) is a progressive neurodegenerative disorder mainly affecting medium
spiny neurons of the striatum. It is the consequence of an expansion of the CAG sequence
in the huntingtin gene that causes the translation of an expanded polyQ tail in the protein.
The symptoms are categorized into motor and cognitive in nature, such as frontal lobe dementia,
and psychiatric symptoms, including depression, anxiety, and psychosis [82]. Fan et al. have published
in vitro evidence that cells overexpressing polyQ-huntingtin, exhibit enhanced CK2 expression [83].
This observation was validated in a mouse model of HD where upregulation of CK2 takes place in
the striatum but not in the cortex. When mice were treated with a pharmacological CK2 inhibitor,
there was a significant increase in NDMAR mediated toxicity which could be explained by the
Pharmaceuticals 2017, 10, 7 10 of 17
phosphorylation-induced endocytosis of NMDAR [5]. Taken together, the possible role of CK2 is to
counteract the toxic effects of the mutant huntingtin gene on NMDAR activity.
One example of a second polyQ disease with pathophysiological involvement of CK2 is
spinocerebellar ataxia type 3. CK2-mediated phosphorylation leads to nuclear accumulation and
aggregation of ataxin 3, indicating that, in the context of this disease, inhibition of CK2 could have the
desirable effect of reducing its nuclear aggregations [84].
6.4. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that involves the loss of
motor neurons of the cortex, brainstem, and spinal cord leading to paralysis and, ultimately, death by
respiratory failure [85]. As in other neurodegenerative diseases, protein aggregates are detected in the
affected areas of the brains of patients, although the aggregated protein may vary in different forms of
the disease. The nuclear RNA-binding protein TDP-43 is, however, found in cytoplasmic inclusions of
all forms of ALS (except in cases of familial ALS with mutations in SOD1).
TDP-43, trapped in the aggregates, undergoes ubiquitination and hyperphosphorylation, and CK2
was found to drive phosphorylation at various sites in cultured cells. Overexpression of CK2
increases phosphorylation, facilitating the solubility of TDP-43 truncated mutants, and this effect
is reversed when cells are treated with a CK2 inhibitor. A Drosophila mutant line expressing a
non-phosphorylatable point mutant developed aggregates in neurons, while a phosphomimicking
mutant failed to do so. These studies suggest that CK2 upregulation and enhanced phosphorylation of
TDP-43 may prevent TDP-43 aggregation and be beneficial for disease outcome [86].
6.5. Alzheimer’s Disease
Late-onset Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the USA
and Europe and is characterized by progressive worsening in cognitive functions along with functional
and behavioral impairments. The pathophysiological hallmarks of the disease are extracellular
insoluble beta amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) composed of
hyperphosphorylated tau aggregates. CK2 activity and protein expression were found to be reduced
in Alzheimer’s disease [87]. CK2 was detected in association with neurofibrillary tangles whose main
component is accumulated and hyperphosphorylated tau [88]. Tau purified from human brain and tau
in neuroblastoma cells are CK2 substrates [89,90].
CK2 was found to phosphorylate Apolipoprotein-E at an atypical site involving proline and an
acidic residue at +1, and interaction of these two partners rendered CK2 more active towards tau in
in vitro kinase assays. However, this data still needs to be confirmed in an in vivo setting [91].
A strong body of evidence suggests that soluble amyloid-β peptide (Aβ) oligomers induce
synaptic loss in AD. Aβ-induced synaptic dysfunction is dependent on overstimulation of N-methyl-
D-aspartate receptors (NMDARs) resulting in aberrant activation of redox events as well as elevation
of cytoplasmic Ca2+, which in turn triggers phosphorylation of tau and the activation of caspases
Cdk5/dynamin-related protein 1 (Drp1) and CaMKII [92]. Dysfunction in these pathways leads to
mitochondrial dysfunction, synaptic malfunction, impaired long-term potentiation, and cognitive
decline. Aβ synaptic toxicity can be partially ameliorated by NMDAR antagonists (such as memantine).
As described in the above section on synaptic transmission (Section 5.2), since Aβwas shown to activate
CK2 in vitro [93], one could hypothesize that CK2 activation leading to enhanced prolonged NMDA
channel opening [49] may be partially responsible for the excessive NMDAR toxicity.
Several laboratories also demonstrated that CK2 is linked to the processing of the amyloid
precursor protein (APP). Walter et al. showed that APP is a substrate for the ectokinase CK2 [94],
after it had been demonstrated by several groups that CK2 can be shed and can phosphorylate
extracellular substrates [95,96]. In neuroblastoma cells, CK2 inhibitor reduced the processing of APP
to soluble sAPPα in response to cholinergic stimulation [97]. sAPPα is generated by α-secretase and
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precludes processing of APP by β and γ-secretases. Thus, this effect caused by CK2 may be desirable,
however, further experiments in this direction need to be undertaken.
As mentioned above, CK2 is activated by Aβ in vitro [93]. Such an activation was proposed to
result in an inhibition of fast axonal transport (FAT), which is a mechanism by which synaptic proteins
and mitochondria are transported from the cell body into axons for proper neuronal function and
survival. Inhibition of CK2 rescued axonal transport and overexpression of active CK2 mimicked the
inhibitory effects of Aβ on FAT. The effect of CK2 on FAT is believed to be mediated by phosphorylation
of kinesin-1 light chains and subsequent release of kinesin from its cargoes, effectively disabling the
transport [98].
However, this finding must be evaluated in the light of data showing that in cultured
mammalian cells, reduction of CK2 expression decreases the number of active kinesin motors [99].
Thus, CK2 up-regulates kinesin-based transport by enhancing the kinesin number but also releasing
kinesin from its cargoes, yielding two functions that counteract each other. Further investigation will
help to resolve the question of which of the effects is predominant in vivo.
Recent human and preclinical studies have provided evidence that impaired insulin signaling
and glucose utilization are contributing to the pathophysiology in AD [100]. It was shown that insulin
and the insulin-sensitizing drug rosiglitazone improve cognitive performance in mouse models of AD
and in patients with early AD [101,102] by reducing binding of Aβ oligomers to synapses. In contrast,
patients with insulin-resistant type 2 diabetes show an increased risk of developing AD [100]. In this
context, it is worthwhile to note that in response to Aβ oligomer binding to hippocampal neurons,
CK2 and CaMKII were found to mediate internalization of the insulin receptor. These findings are in
several ways reminiscent of CK2’s role in NDMAR endocytosis (as discussed in Section 5.2) since both
require CaMKII and are dependent on receptor activity.
Other groups have already identified a role for CK2 in the non-neuronal insulin pathway
as described in Section 5.1, CK2 negatively modulates insulin release from pancreatic beta cells,
in a manner that depends on the M3 receptor [43]. While this work is discussed in the realm of glucose
intolerance and diabetes type 2, one could extend a hypothesis here to question if pharmacological
CK2 inhibition might benefit Alzheimer’s patients.
Neuroinflammation, as detected by the presence of activated complement proteins interleukins
and chemokines in microglia, and astrocytes are is increased in AD [103]. Although neuroinflammation
in the brain of AD patients is considered primarily beneficial (eliminating injurious stimuli and
restoring tissue integrity), a chronic neuroinflammatory response may be harmful due to the
constant excess of pro-inflammatory cytokines, prostaglandins, and reactive oxygen species. A recent
immunohistochemical study detected increased amounts of CK2α or α′ in the hippocampus and
temporal cortex of AD patients in astrocytes surrounding amyloid deposits [104]. It remains to be
determined whether this increase is of functional consequence.
In summary, CK2 plays a role in several mechanisms that are involved in tau phosphorylation,
APP processing, Aβ signaling, and protective responses to Aβ insults such as neuroinflammatory
responses and insulin signaling.
7. Conclusions
In summary, it comes as no surprise that CK2 plays a major role in a variety of processes in the
brain, as it has been shown to target a vast number of brain proteins. In the context of brain disorders,
one would like to assess whether CK2 may be a good target for modifying disease outcome and
or progression.
The case for glioblastoma is clear, and several preclinical studies have demonstrated the beneficial
effect of CK2 inhibitors on tumor size reduction as well as patient survival.
For Huntington’s disease and ALS, there is currently no rationale to argue for CK2 as a target to
interfere with disease progression, while in the case of type 3 spinocerebellar ataxia, CK2 inhibition
may be desirable and result in a reduction in ataxin aggregation.
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In the context of Alzheimer’s disease, most known factors would argue that, even though CK2
expression was shown to be reduced, a further inhibition of CK2 through pharmacological means
may be beneficial in reducing the burden of hyperphosphorylated tau and neurofibrillary tangles.
It may also be beneficial to prevent or reduce insulin receptor internalization and to rescue fast axonal
transport that is disabled by Aβ. However, CK2 activity may be desirable due to its endocytotic effect
on NMDAR.
In order to ascertain how the various mechanisms of CK2 involvement in neurological disease
pathology are integrated in vivo, it is preferable to use a conditional CK2 KO, possibly even in an
inducible version, and cross the KO mice into appropriate preclinical models of neurodegenerative
diseases. The genetic approach is, in our opinion, preferable for proof of concept experiments because
the available inhibitors are not readily blood-brain barrier permeable and, thus, require relatively
high-dose administration which will also affect peripheral sites and a variety of centrally mediated
behaviors that are unrelated to disease pathologies.
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